/
IMA
$6.07+$0.05 (+0.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$67.9M
11M shares
52-week range
$3.94 – $18.00
15% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
2.45%
Moderate
Price (6 mo)
Loading chart…
Change$-10.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $990.0K | $13.8M | $9.2M | $31.0M | $15.6M | $9.2M | $3.5M | $800.0K |
| Cost of revenue | $39.0M | $24.9M | $44.8M | $47.1M | $64.3M | $1.0M | $1.5M | $1.0M |
| Gross profit | −$38.0M | −$11.2M | −$35.7M | −$16.1M | −$48.7M | $8.1M | $3.5M | −$233.0K |
| Gross margin | -3838.0% | -81.3% | -387.8% | -52.0% | -311.8% | 88.9% | 100.0% | -29.1% |
| R&D | $38.6M | $24.9M | $44.8M | $47.1M | $64.3M | $59.7M | $32.1M | $28.5M |
| Operating income | −$40.9M | −$18.5M | −$44.5M | −$34.1M | −$70.9M | −$75.4M | −$37.0M | −$48.5M |
| EBITDA | −$40.4M | −$18.2M | −$44.2M | −$33.6M | −$68.0M | −$67.3M | −$35.0M | −$44.7M |
| Net income | −$40.9M | −$16.8M | −$44.3M | −$34.1M | −$68.8M | −$68.2M | −$36.6M | −$45.3M |
| Net margin | -4127.8% | -122.3% | -481.4% | -110.1% | -440.3% | -744.2% | -1044.8% | -5668.6% |
| EPS (diluted) | -1.14 | -0.47 | -3.16 | -0.95 | -1.90 | -1.63 | -1.02 | -10.76 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $340244 | $-4.10 | $-4.20–$-3.99 | 2 |
| 2027 | $144707 | $-3.07 | $-4.59–$-1.54 | 2 |
| 2028 | $61544 | $-3.95 | $-5.48–$-1.01 | 3 |
| 2029 | $26175 | $-3.57 | $-3.57–$-3.57 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.99
Price
$6.07
Implied downside
-18%
Peer comparison
ImageneBio, Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
www.imagenebio.com- Employees
- 17
- IPO / List date
- Jul 28, 2025
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds IMA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 81,696 | $408.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMA yet.
